A new survey suggests that most Americans are familiar with statins, but most are not aware of nonstatin cholesterol-lowering therapies and other tools to combat heart disease.The survey of 1,006 ...

Please provide your email address to receive an email when new articles are posted on . In the STEP trials, a higher proportion of adults receiving semaglutide stopped antihypertensive or ...

Sanofi and Regeneron’s PCSK9 inhibitor alirocumab—one of a group of antibodies heralded as the next class of cholesterol-lowering agents—has had its day in the Barcelona sun at the European Society of ...

An experimental once-daily pill called enlicitide cut LDL cholesterol by 57% in a large Phase 3 clinical trial, a result ...

PHILADELPHIA -- A novel anti-PCSK9 monoclonal antibody with a distinctive longer duration of action reduced cholesterol and other lipids in the phase III REMAIN-2 trial. Recaticimab showed long-term ...

CKD patients face higher CVD risk, with dyslipidemia differing from the general population, necessitating tailored lipid management strategies. Statin-based therapies, especially simvastatin plus ...

Older patients who have been discharged from the hospital after myocardial infarction are at a significantly lower risk of all-cause mortality if treated with high-intensity lipid-lowering therapy, ...

November 25, 2011 (Orlando, Florida) — Weekly subcutaneous injection of the investigational lipid-lowering agent mipomersen (Genzyme) was associated with a 47% reduction in low-density lipoprotein ...

Another study explored goldenseal’s antioxidant activity as it applied to cholesterol. In an in vivo study with rats, all rats were given a high-cholesterol diet and then randomly assigned to either ...